Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children

Objective

Childhood Tuberculous meningitis (TBM) is the most severe form of tuberculosis (TB), mostly affecting children. Diagnosis of TBM in children is challenging, necessitating up to six visits to hospitals. Furthermore, 50% of people who are diagnosed with TBM die or suffer life-long neurological problems. We previously identified, patented, and validated a 3-protein cerebrospinal fluid (CSF) biomarker signature, including IFN-γ, for the diagnosis of childhood TBM. We have developed a prototype point-of-care (PoC) lateral flow test based on this biosignature, in collaboration with LifeSADX, an industrial partner based in South Africa. We also developed a variant of the CSF-based test, based on the biosensor technology and have identified blood-based (BB) biomarkers which require refinement and subsequent development into a TBM PoC test. The potential alterations of IFN-γ detection or function due to autoantibodies or genetic mutations in these patients is currently unknown.
In this project, we aim to:
1) Gather evidence on the performances of the two newly developed CSF-based PoC tests at hospitals situated in South Africa, Zambia, and Zimbabwe
2) Refine our previously identified BB-biosignature in stored multi-country specimens, and incorporate the refined biomarkers into a new TBM prototype test, using biosensor technology
3) Prospectively evaluate the blood-based prototype test alongside the CSF-based tests
4) Test both immunologically and genetically, defects in IFN-γ immunity, a key biomarker on our CSF-based tests, in CSF and serum samples, and ascertain the relevance of such defects to possible disease development, and their influence on PoC test results
The project will bring together a multi-disciplinary team with different but complementary expertise including immunologists, human geneticists, neurologists, social scientists, and an industrial partner based in South Africa, and has potential to significantly influence the management of childhood TBM worldwide.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2025-04-two-stage

See all projects funded under this call

Coordinator

STELLENBOSCH UNIVERSITY
Net EU contribution
€ 429 020,00
Address
VICTORIA STREET ADMINISTRATION B BUILDING
7600 Stellenbosch
South Africa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 429 020,00

Participants (5)